A Current Practice Snapshot of RA Management: Where We Are, Where We Need to Be, and Where JAK Inhibitors Fit

A Current Practice Snapshot of RA Management: Where We Are, Where We Need to Be, and Where JAK Inhibitors Fit

Online Course | Specialties: Rheumatology
Released: 6/28/2021
Expires: 6/27/2022
Max Credits: 1.0
Jump to Education

Jeffrey Curtis, MD, MS, MPH
Professor of Medicine, Division of Clinical Immunology and Rheumatology
Marguerite Jones Harbert – Gene Ball Endowed Professor of Medicine
Co-Director, UAB Pharmacoepidemiology and Pharmacoeconomics Research Unit
University of Alabama at Birmingham
Birmingham, AL

Elena Myasoedova, MD, PhD
Associate Professor of Medicine
Senior Associate Consultant
Mayo Clinic
Rochester, MN

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Baltimore, MD

Rebecca Julian, MS, ELS
Senior Manager, Editorial
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
East Lansing, MI

Ron Schaumburg
Wynnewood, PA

Learning Objectives
Upon completion, participants should be able to:

  • Describe the benefits of proactive management with DMARD therapy on morbidity, mortality, quality of life, and healthcare costs for patients with RA
  • Apply recent updates to RA treatment guidelines on individualizing management strategies for patients with RA whose disease is inadequately controlled
  • Discuss the clinical trial data supporting the safety and efficacy of available and investigational JAKis, their specific mechanisms, and their evidence-based role in managing patients with RA
  • Recognize adjustments needed in immunomodulatory therapy for patients with RA who are candidates for COVID-19 vaccination or who have been exposed to or are infected with SARS-CoV-2 virus
  • Identify key strategies and messaging to educate patients using immunomodulatory therapy for RA to improve treatment outcomes

Target Audience
This activity is intended for rheumatology clinicians, including physicians, physician assistants, nurse practitioners, nurses, fellows, and residents.

Statement of Need
Many patients with RA do not achieve an adequate response with standard therapies. Intolerance, nonresponse, and loss of response are commonly associated with many of the conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) used for the treatment of RA. Furthermore, many clinicians do not adhere to the guideline-recommended treat-to-target paradigm and neglect to make changes to patients’ therapy in the presence of high disease activity, exposing patients to poor disease outcomes and decreased quality of life. The recently updated European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) RA guidelines provide guidance on RA treatment, including the use of Janus kinase (JAK) inhibitors. Rheumatology clinicians need education that outlines the evolving standard of care so they are prepared to provide individualized solutions to patients with RA that address their disease management needs and align with their personal treatment-related preferences and goals.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This nursing activity has been approved for up to 1.0 contact hour.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME/CE activity consists of a 1.0-credit online publication. To receive credit, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: June 28, 2021
Expiration Date: June 27, 2022
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Jeffrey Curtis, MD, MS, MPH
Consulting fees/advisory boards: AbbVie Inc., Amgen, Bristol Myers-Squibb, Corrona, Janssen Pharmaceuticals, Inc., Myriad Genetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Amgen, Bristol Myers-Squibb, Corrona, Janssen Pharmaceuticals, Inc., Myriad Genetics, Pfizer, Inc., Sanofi-aventis U.S. Inc.

Elena Myasoedova, MD, PhD, has indicated no real or apparent conflicts.

Ron Schaumburg has indicated no real or apparent conflicts.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.



Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • Many patients with RA do not achieve an adequate response with standard therapies
  • Updated ACR RA guidelines published in 2021 provide guidance on initial RA treatment and recommendations for patients who are not at target; specifically, the guidelines recommend that:
    • Patients be evaluated at the 3-month mark and, if results prove unsatisfactory, the treatment strategy should be adjusted accordingly to improve the likelihood of reaching LDA targets
    • Clinicians take into account the individual patient’s values, preferences, and comorbidities to achieve optimal outcomes from RA therapy and tailor the strategy to meet that individual’s needs, an approach known as shared decision making

Click “Continue” to proceed through this activity and/or receive credit.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.